Alzheimer’s disease has beaten back another effort to tame it.

Biogen and its Japanese pharma partner Eisai said Thursday that they were halting two Phase 3 clinical trials of aducanumab, a drug that was designed to slow the worsening of Alzheimer’s by targeting brain-destroying protein fragments known as beta-amyloid.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • wow all the eggs in one basket just brilliant, lost 16 BILLION dollars…yet I’ll bet the CEO makes millions in bonuses and if made to leave which they should be, will get a golden parachute worth MILLIONS for nearly destroying or who knows maybe actually destroying a company

  • No doubt AA removing the plaques should work to improve the outcome of the disease but the wholes remain and the disease would progress

  • Trying to stop Alzheimer’s once it is going, is a hopeless proposition unless somebody can show that neural cells can regenerate. A situation that we now is unreal. Removing plaque can create more problems, plaque immobilizes toxic amyloid-beta oligomers, hence removing plaque increases the concentration of free toxic components. While aducanumab may have protective effects, there are myriad amyloid beta oligomers, which means you would need an array of antibodies to block the different flavors of toxic amyloid. Perhaps a mixture of different antibodies would be more effective. Once amyloid oligomers are formed, they promote tau phosphorylation that amplifies damage; thus, an after the facts blocking of amyloid oligomers is too late too little. Finally, immune prevention is a more realistic goal than try to cure what apparently is incurable

    • I wonder if anyone tried going other way. Pushing oligomerization toward plaques – to prevent toxicity of oligomers. As far as I understand plaque amounts in brain do not correlate to AD symptoms (i.e healthy individuals might have more plaques than AD patients). It is very disappointing and very sad for families with AD patients. 🙁

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy